Development Of Lipid Nanoparticles and Application in Drug Delivery Systems
DOI:
https://doi.org/10.54097/jpqjbg39Keywords:
Lipid nanoparticles; Cancer therapy; Drug delivery system; Mrna; Neurological diseases.Abstract
The most clinically developed non-viral gene delivery method available today is lipid nanoparticles (LNPs), which can efficiently encapsulate a variety of medications, including proteins, nucleic acids (like mRNA and siRNA), and small molecules. LNPs greatly enhance drug stability, targeting and bioavailability, and through modification of the specific ligands on the surface, enable precise delivery to specific cells or tissues with reduced uptake by off-target cells and reduced side effects. By modifying specific ligands on their surfaces, they can achieve precise delivery to specific cells or tissues, reduce uptake in non-target cells and minimize side effects. The composition of LNPs is described in this paper along with their usage in cancer treatment, where gene editing is made possible through the CRISPR/Cas9 technology and LNPs can be combined with immunotherapeutic and chemotherapeutic medicines for multimodal therapy. Applications of LNPs in the treatment of neurological illnesses and in nucleic acid drug delivery systems are also covered. LNPs can be used to deliver siRNAs and mRNAs and protect them from degradation for targeted delivery. LNPs can also be employed for brain-targeted medication delivery by altering ligands such as lactoferrin, transferrin and others.
Downloads
References
[1] Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021). Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS nano, 15(11), 16982–17015.
[2] Guo, J., Gu, M., Chen, Y., Xiong, T., Zhang, Y., Chen, S., Li, M., Chen, X., & Peng, X. (2025). Nucleic acid delivery by lipid nanoparticles for organ targeting. Chinese Chemical Letters, 110849.
[3] Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019). Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Molecular Therapy, 27(4), 710–728. https://doi.org/10.1016/j.ymthe.2019.02.012
[4] Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021). Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews, 170, 83–112.
[5] Du, X. (2024). Review of the development and application of lipid nanoparticle in tumor therapy., by X. Li. Pharmaceutical Research, (11), 1116-1124+1140.
[6] S. Ramishetti, I. Hazan-Halevy, R. Palakuri, S. Chatterjee, S. NaiduGonna, N. Dammes, I. Freilich, L. KolikShmuel, D. Danino, D. Peer, A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Adv. Mater. 2020, 32, 1906128.
[7] Cheng, Z., Huang, H., Yin, M. et al. Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects. Exp Hematol Oncol 14, 11 (2025).
[8] Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., Wu, J. L. Y., Wilhelm, S., Zilman, A., Gadde, S., Sulaiman, A., Ouyang, B., Lin, Z., Wang, L., Egeblad, M., & Chan, W. C. W. (2020). The entry of nanoparticles into solid tumours. Nature materials, 19(5), 566–575.
[9] Zhou, Y., Ge, Q., Wang, X., Wang, Y., Sun, Q., Wang, J., … Wang, C. (2025). Advances in Lipid Nanoparticle‐Based Disease Treatment. ChemMedChem.
[10] Li, C., Yang, T., Weng, Y., Zhang, M., Zhao, D., Guo, S., Hu, B., Shao, W., Wang, X., Hussain, A., Liang, X. J., & Huang, Y. (2021). Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioactive materials, 9, 590–601.
[11] Liu, Z., Wang, Q., Feng, Y., Zhao, L., Dong, N., Zhang, Y., … Yang, L. (2023). The self-adjuvant heterocyclic lipid nanoparticles encapsulated with vaccine and STAT3 siRNA boost cancer immunotherapy through DLN-targeted and STING pathway. Chemical Engineering Journal, 475, 146474–146474.
[12] Jiang, Y., Zhang, Y., Liu, C., Liu, J., Xue, W., Wang, Z., & Li, X. (2024). Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy. Journal of controlled release: official journal of the Controlled Release Society, 368, 663–675.
[13] El Dika, I., Lim, H. Y., Yong, W. P., Lin, C. C., Yoon, J. H., Modiano, M., Freilich, B., Choi, H. J., Chao, T. Y., Kelley, R. K., Brown, J., Knox, J., Ryoo, B. Y., Yau, T., & Abou-Alfa, G. K. (2019). An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. The oncologist, 24(6), 747–e218.
[14] Liu, S., Cheng, Q., Wei, T., Yu, X., Johnson, L. T., Farbiak, L., & Siegwart, D. J. (2021). Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas’s gene editing. Nature materials, 20(5), 701–710.
[15] Fan, Y., Yin, H., Li, Y., Yu, X., & Tang, X. (2024). Review of Progress on mRNA vaccines and lipid nanoparticles., by Y. Huang. Science Bulletin, (33), 4813–4823.
[16] Mubarak, N., Waqar, M. A., Khan, A. M., Asif, Z., Alvi, A. S., Virk, A. A., & Amir, S. (2025). A comprehensive insight of innovations and recent advancements in nanocarriers for nose-to-brain drug targeting. Designed monomers and polymers, 28(1), 7–29.
[17] Jang, Y. J., Kang, S. J., Park, H. S., Lee, D. H., Kim, J. H., Kim, J. E., Kim, D. I., Chung, C. H., Yoon, J. K., & Bhang, S. H. (2025). Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment. Journal of nanobiotechnology, 23(1), 99.
[18] Senapati, S., Tripathi, K., Awad, K., & Rahimipour, S. (2024). Multifunctional Liposomes Targeting Amyloid-β Oligomers for Early Diagnosis and Therapy of Alzheimer's Disease. Small (Weinheim an der Bergstrasse, Germany), 20(31), e2311670.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
